Efficacy Demonstrated Established
For the TAXUS II International Efficacy Trial data in portable document format,
click here.
| Objective: |
Demonstrate safety and efficacy of Paclitaxel-Eluting NIR® Stent for the treatment of de novo lesions. |
| Number of Patients: |
536 |
| Lesion Type: |
de novo, = 12 mm length, 3.0-3.5 mm vessel diameter |
| Stent Platform: |
NIR® Conformer 15 mm |
| Release Kinetics: |
Slow and Moderate |
| Primary Endpoint: |
6-month % net volume obstruction |
| Principal Investigator: |
Antonio Colombo, MD |
| Status: |
Enrollment complete, 6- and 12-month follow-up presented, patients now in 24-month follow-up |
NIR is a registered trademark of Medinol, Ltd. Jerusalem, Israel
